Earnings Call · Q4 FY2022·2023-03-31

Q4 22EPS -14.75%·Rev n/aQ3 22EPS -10.45%·Rev n/aQ2 22EPS -68.42%·Rev n/aQ1 22EPS +6.25%·Rev n/a⚠ consensus missing

Processa Pharmaceuticals, Inc. PCSA

Jim Stanker — Chief Financial Officer

David Young — Chief Executive Officer

Unidentified Analyst — Analyst

Naz Rahman — Analyst

+4.2%1d on move date+2.8% vs SPY3d+2.1%5d−2.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PCSA calls or request research access.

More PCSA calls Browse calls Request research access